Reference/Treatment

Patients

Prior treatment

Efficacy response (%)

Survival analysis

PFS

Overall survival

Total No.

Radiation Therapy and Chemotherapy %

Chemotherapy %

CR

PR

Median (mos)

6 mos %

Median (mos)

6 mos %

1 y %

2 y %

10 y %

Vredenburgh et al., 2007 Bevacizumab and irinotecan [25]

23

All

TMZ-All

4

56

4.6

30

9.3

Reardon et al., 2011 Carboplatin, irinotecan and bevacizumab [26]

25

All

TMZ-All Bevacizumab

0

0

2.3

16

5.8

Desjardins et al., 2012 Bevacizumab and daily TMZ [27]

32

All

TMZ-All

0

28

3.6

18.8

8.6

31

8

Omuro et al., 2013 Low-dose TMZ [20]

28^*

All

TMZ-All

0

11

2

19

7

35

Burzynski et al., 2014 Antineoplastons A10 and AS2-1 RGBM

30

57^**

10

6.7

6.7

2.1

16.7

8.3

55.5

34.7

3.5

3.5

Burzynski et al., 2014 Antineoplastons A10 and AS2-1 ERGBM

24

62.5^***

25

8.3

8.3

2.4

20.8

11.5

65.5

39.3

4.4

4.4